Table 5. QTL candidate gene SNPs associated with aggressive prostate cancer in CGEMS GWAS.
Chr. | Candidate Gene | SNP Distance From Gene (bp) | SNP | PLCO Variable | Odds Ratio (95% C.I.) | Minor Allele Frequency | t stat | P value | Permutation P value | |
Aggressive Disease | Non-Aggressive Disease | |||||||||
5q31.1 | CXCL14 | 97285 | rs801564 | pros_stage_n | 1.05 (1.01–1.09) | 0.001 | 0.282 | 2.587 | 0.010 | 0.011 |
47017 | rs10515473 | pros_gleason_prost | 0.72 (0.59–0.88) | 0.163 | 0.122 | −3.148 | 0.002 | 0.001 | ||
6p22.1 | HIST1H3E | 6834 | rs933199 | pros_gleason | 0.75 (0.62–0.92) | 0.032 | 0.025 | −2.759 | 0.006 | 0.006 |
17168 | rs198806 | pros_gleason_prost | 0.77 (0.63–0.93) | 0.218 | 0.172 | −2.643 | 0.008 | 0.009 | ||
PGBD1 | 31884 | rs1233708 | pros_stage | 1.08 (1.02–1.13) | 0.042 | 0.213 | 2.921 | 0.004 | 0.004 | |
6p22.2 | HIST1H1A | 13705 | rs6910741 | pros_stage_n | 0.94 (0.90–0.98) | 0.002 | 0.144 | −2.620 | 0.009 | 0.009 |
6p22.3 | GPLD1 | 0 | rs793663 | pros_gleason_prost | 1.32 (1.09–1.60) | 0.186 | 0.195 | 2.854 | 0.004 | 0.004 |
37981 | rs3789224 | pros_stage_m | 1.08 (1.02–1.13) | 4.06E-04 | 0.127 | 2.627 | 0.009 | 0.010 | ||
6q15 | AKIRIN2 | 0 | rs7755167 | pros_gleason | 0.86 (0.78–0.95) | 0.246 | 0.221 | −3.107 | 0.002 | 0.002 |
ORC3 | 40224 | rs9450716 | pros_gleason | 1.16 (1.05–1.28) | 0.161 | 0.189 | 3.042 | 0.002 | 0.002 | |
9p13.3 | CCL19 | 80925 | rs3802427 | pros_stage_m | 1.09 (1.04–1.15) | 4.06E-04 | 0.162 | 3.557 | 3.89E-04 | 3.00E-04 |
KIAA1045 | 78052 | rs10123308 | pros_gleason_prost | 1.30 (1.08–1.57) | 0.212 | 0.216 | 2.773 | 0.006 | 0.005 | |
9p21.2 | MOB3B | 3431 | rs3849942 | pros_stage_t | 2.15 (1.41–3.28) | 0.161 | 0.075 | 3.564 | 3.80E-04 | 5.00E-04 |
0 | rs3739530 | pros_gleason | 0.80 (0.70–0.93) | 0.075 | 0.056 | −2.996 | 0.003 | 0.002 | ||
74176 | rs1853186 | pros_stage | 0.94 (0.90–0.98) | 0.079 | 0.272 | −2.730 | 0.006 | 0.006 | ||
0 | rs10121765 | pros_gleason_prost | 0.77 (0.64–0.93) | 0.260 | 0.209 | −2.776 | 0.006 | 0.005 | ||
16p11.2 | ITGAX | 9009 | rs8045738 | pros_gleason_prost | 1.33 (1.08–1.62) | 0.141 | 0.148 | 2.753 | 0.006 | 0.007 |
16q12.2 | LPCAT2 | 19704 | rs3764263 | pros_stage_t | 1.61 (1.12–2.31) | 0.324 | 0.134 | 2.591 | 0.010 | 0.009 |
0 | rs289707 | pros_gleason_biop | 1.22 (1.07–1.38) | 0.075 | 0.126 | 3.059 | 0.002 | 0.002 | ||
72508 | rs2289119 | pros_stage_n | 1.06 (1.01–1.10) | 0.001 | 0.187 | 2.591 | 0.010 | 0.009 | ||
0 | rs17369578 | pros_gleason | 1.41 (1.13–1.77) | 0.020 | 0.026 | 2.976 | 0.003 | 0.003 | ||
20p11.21 | GZF1 | 836 | rs6076072 | pros_stage_t | 2.17 (1.21–3.92) | 0.068 | 0.035 | 2.589 | 0.010 | 0.008 |
20p13 | NSFL1C | 4463 | rs6042568 | pros_gleason | 0.75 (0.62–0.90) | 0.037 | 0.029 | −3.007 | 0.003 | 0.003 |
QTL candidate genes also identified as having a dysregulated expression in prostate cancer gene expression datasets are denoted in bold typeface.